当前位置: 首页 >> 检索结果
361. Baseline regional perfusion impacts exercise response to endobronchial valve therapy in advanced pulmonary emphysema.
作者: Rahul G Argula.;Charlie Strange.;Viswanathan Ramakrishnan.;Jonathan Goldin.
来源: Chest. 2013年144卷5期1578-1586页
Advanced heterogeneous emphysema with hyperinflation impacts exercise tolerance in COPD. Bronchoscopic lung volume reduction using Zephyr endobronchial valves (EBVs) has been shown to improve lung function in patients with heterogeneous emphysema. It is unclear whether the target lobe perfusion of patients receiving EBV therapy impacts exercise tolerance as measured by the 6-min walk test distance (6MWTD).
362. Clinical outcomes of indwelling pleural catheter-related pleural infections: an international multicenter study.
作者: Edward T H Fysh.;Alain Tremblay.;David Feller-Kopman.;Eleanor K Mishra.;Mark Slade.;Luke Garske.;Amelia O Clive.;Carla Lamb.;Rogier Boshuizen.;Benjamin J Ng.;Andrew W Rosenstengel.;Lonny Yarmus.;Najib M Rahman.;Nick A Maskell.;Y C Gary Lee.
来源: Chest. 2013年144卷5期1597-1602页
Indwelling pleural catheters (IPCs) offer effective control of malignant pleural effusions (MPEs). IPC-related infection is uncommon but remains a major concern. Individual IPC centers see few infections, and previous reports lack sufficient numbers and detail. This study combined the experience of 11 centers from North America, Europe, and Australia to describe the incidence, microbiology, management, and clinical outcomes of IPC-related pleural infection.
363. Is it possible to identify exacerbations of mild to moderate COPD that do not require antibiotic treatment?
作者: Marc Miravitlles.;Ana Moragas.;Silvia Hernández.;Carolina Bayona.;Carl Llor.
来源: Chest. 2013年144卷5期1571-1577页
Anthonisen criteria are widely used to guide the use of antibiotics in exacerbations of COPD. We evaluated the best predictors of outcomes in exacerbations of mild to moderate COPD not treated with antibiotics.
364. Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes.
作者: David R Williamson.;Martin Albert.;Diane Heels-Ansdell.;Donald M Arnold.;François Lauzier.;Ryan Zarychanski.;Mark Crowther.;Theodore E Warkentin.;Peter Dodek.;John Cade.;Olivier Lesur.;Wendy Lim.;Robert Fowler.;Francois Lamontagne.;Stephan Langevin.;Andreas Freitag.;John Muscedere.;Jan O Friedrich.;William Geerts.;Lisa Burry.;Jamal Alhashemi.;Deborah Cook.; .
来源: Chest. 2013年144卷4期1207-1215页
Thrombocytopenia is the most common hemostatic disorder in critically ill patients. The objective of this study was to describe the incidence, risk factors, and outcomes of thrombocytopenia in patients admitted to medical-surgical ICUs.
365. Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study.
作者: Fanny Lanternier.;Florence Tubach.;Philppe Ravaud.;Dominique Salmon.;Pierre Dellamonica.;Stephane Bretagne.;Marie Couret.;Beatrice Bouvard.;Michel Debandt.;Isabelle Gueit.;Jean-Pierre Gendre.;Jean Leone.;Nathalie Nicolas.;Dider Che.;Xavier Mariette.;Olivier Lortholary.; .
来源: Chest. 2013年144卷3期990-998页
Our objective was to describe the incidence and risk factors of legionellosis associated with tumor necrosis factor (TNF)-α antagonist use.
366. Whole blood lactate kinetics in patients undergoing quantitative resuscitation for severe sepsis and septic shock.
作者: Michael A Puskarich.;Stephen Trzeciak.;Nathan I Shapiro.;Andrew B Albers.;Alan C Heffner.;Jeffrey A Kline.;Alan E Jones.
来源: Chest. 2013年143卷6期1548-1553页
We sought to compare the association of whole-blood lactate kinetics with survival in patients with septic shock undergoing early quantitative resuscitation.
367. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.
作者: MeiLan K Han.;David S Bach.;Peter G Hagan.;Eric Yow.;Kevin R Flaherty.;Galen B Toews.;Kevin J Anstrom.;Fernando J Martinez.; .
来源: Chest. 2013年143卷6期1699-1708页
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with pulmonary vasculopathy.
368. Heparin-induced thrombocytopenia in medical surgical critical illness.
作者: Theodore E Warkentin.;Jo-Ann I Sheppard.;Diane Heels-Ansdell.;John C Marshall.;Lauralyn McIntyre.;Marcelo G Rocha.;Sangeeta Mehta.;Andrew R Davies.;Andrew D Bersten.;Tim M Crozier.;David Ernest.;Nicholas E Vlahakis.;Richard I Hall.;Gordon G Wood.;Germain Poirier.;Mark A Crowther.;Deborah J Cook.; .
来源: Chest. 2013年144卷3期848-858页
In a recent multicenter randomized trial comparing unfractionated heparin (UFH) with low-molecular-weight heparin (dalteparin) for thromboprophylaxis in 3,746 critically ill patients, 17 patients (0.5%) developed heparin-induced thrombocytopenia (HIT) based on serotonin-release assay-positive (SRA+) status. A trend to a lower frequency of HIT with dalteparin vs UFH was observed in the intention-to-treat analysis (five vs 12 patients, P = .14), which was statistically significant (three vs 12 patients, P = .046) in a prespecified per-protocol analysis that excluded patients with DVT at study entry. We sought to characterize HIT outcomes and to determine how dalteparin thromboprophylaxis may reduce HIT frequency in patients in the ICU.
369. Effect of increased blood levels of β-endorphin on perception of breathlessness.
作者: Donald A Mahler.;Alex H Gifford.;Laurie A Waterman.;Joseph Ward.;William J Kraemer.;Brian R Kupchak.;Andrew Harver.
来源: Chest. 2013年143卷5期1378-1385页
Although opioid receptors are expressed broadly in the CNS and in peripheral sensory nerve endings including bronchioles and alveolar walls of the respiratory tract, it is unknown whether the modulatory effect of endogenous opioids on breathlessness occurs in the CNS or in the peripheral nervous system. The purpose of this investigation was to examine whether increased blood levels of β-endorphin modify breathlessness by a putative effect of binding to peripheral opioid receptors in the respiratory tract.
370. CPAP improves endothelial function in patients with minimally symptomatic OSA: results from a subset study of the MOSAIC trial.
作者: Malcolm Kohler.;Sonya Craig.;Justin C T Pepperell.;Debby Nicoll.;Daniel J Bratton.;Andrew J Nunn.;Paul Leeson.;John R Stradling.
来源: Chest. 2013年144卷3期896-902页
Minimally symptomatic OSA is a highly prevalent disorder, and the effects of CPAP on vascular function in these patients are unknown. This trial aimed to investigate whether CPAP improves vascular function in minimally symptomatic OSA.
371. Longitudinal trends in health-related quality of life in adults with cystic fibrosis.
作者: Edward J Dill.;Ree Dawson.;Deborah E Sellers.;Walter M Robinson.;Gregory S Sawicki.
来源: Chest. 2013年144卷3期981-989页
Health-related quality-of-life (HRQOL) measures have been used as patient-reported outcomes in clinical trials in cystic fibrosis (CF), but there are limited data on HRQOL changes over time in adults with CF.
372. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score.
作者: Stavros Apostolakis.;Renee M Sullivan.;Brian Olshansky.;Gregory Y H Lip.
来源: Chest. 2013年144卷5期1555-1563页
When oral anticoagulation with adjusted-dose vitamin K antagonist (VKA) is used, the quality of anticoagulation control (as reflected by the time in therapeutic range [TTR] of the international normalized ratio [INR]) is an important determinant of thromboembolism and bleeding. Our objective was to derive a validated scheme using patient-related clinical parameters to assess the likelihood of poor INR control among patients with atrial fibrillation (AF) on VKA therapy.
373. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
作者: Victor F Tapson.;Zhi-Cheng Jing.;Kai-Feng Xu.;Lei Pan.;Jeremy Feldman.;David G Kiely.;Eugene Kotlyar.;C Shane McSwain.;Kevin Laliberte.;Carl Arneson.;Lewis J Rubin.; .
来源: Chest. 2013年144卷3期952-958页
Treprostinil is a stable prostacyclin analog approved for the treatment of pulmonary arterial hypertension (PAH) as parenteral or inhaled therapy. Treprostinil diolamine, a sustained-release oral formulation of treprostinil, was studied to determine whether it could provide a more convenient prostacyclin treatment option for patients with less severe PAH. The objective of this study was to evaluate the efficacy and safety of oral treprostinil in patients with PAH receiving stable background endothelin receptor antagonist (ERA), phosphodiesterase type 5 inhibitor (PDE-5I) therapy, or both.
374. Effects of OSA treatment on BP in patients with resistant hypertension: a randomized trial.
作者: Rodrigo P Pedrosa.;Luciano F Drager.;Lílian K G de Paula.;Aline C S Amaro.;Luiz A Bortolotto.;Geraldo Lorenzi-Filho.
来源: Chest. 2013年144卷5期1487-1494页
OSA is extremely common among patients with resistant hypertension (HTN). However, the impact of the treatment of OSA with CPAP on BP in patients with resistant HTN is not well established.
375. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma.
作者: Gilles Garcia.;Antoine Magnan.;Raphaël Chiron.;Cécile Contin-Bordes.;Patrick Berger.;Camille Taillé.;Gilles Devouassoux.;Frédéric de Blay.;Louis-Jean Couderc.;Alain Didier.;Dermot S O'Callaghan.;Pierre-Olivier Girodet.;Isabelle Bourdeix.;Vincent Le Gros.;Marc Humbert.
来源: Chest. 2013年144卷2期411-419页
While up to 50% of patients with severe asthma have no evidence of allergy, IgE has been linked to asthma, irrespective of atopic status. Omalizumab, an anti-IgE monoclonal antibody, is reported to significantly benefit a subset of patients with severe, persistent, allergic asthma. Therefore, we investigated whether omalizumab has biologic and clinical effects in patients with refractory nonatopic asthma.
376. Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trial.
作者: Christopher B Cooper.;Bartolome R Celli.;José R Jardim.;Robert A Wise.;Daniel Legg.;Junhai Guo.;Steven Kesten.
来源: Chest. 2013年144卷2期490-497页
Disease progression in COPD is associated with a decline in exercise performance over time. We assessed whether tiotropium might mitigate this by determining its effect on treadmill endurance time (ET) over 2 years.
377. Acute bronchodilator responsiveness to tiotropium in postinfectious bronchiolitis obliterans in children.
作者: Mariângela F C Teixeira.;Joaquim C Rodrigues.;Claudio Leone.;Fabíola V Adde.
来源: Chest. 2013年144卷3期974-980页
Patients with postinfectious bronchiolitis obliterans (PIBO) usually have severe airflow obstruction and respond poorly to β-adrenergic drugs. However, the bronchodilator response to an anticholinergic agent such as tiotropium bromide is not known. We studied the acute bronchodilator response to tiotropium for up to 24 h in children with PIBO using spirometric and plethysmographic criteria.
378. Validation of the Cough Quality-of-Life Questionnaire in patients with idiopathic pulmonary fibrosis.
Cough is a pervasive and disabling symptom of idiopathic pulmonary fibrosis (IPF) and is an independent predictor of disease progression. The Cough Quality-of-Life Questionnaire (CQLQ) is a validated measure of cough-specific quality of life that could be used as an outcome measure in therapeutic trials for IPF. This study aimed to assess the reliability and validity of the CQLQ in individuals with IPF.
379. A prospective study of respiratory viral infection in pregnant women with and without asthma.
作者: Vanessa E Murphy.;Heather Powell.;Peter A B Wark.;Peter G Gibson.
来源: Chest. 2013年144卷2期420-427页
Respiratory viral infections are common in pregnancy, but their health impact, especially in asthma, is unknown. The objective of this study was to assess the frequency, severity, and consequences of respiratory viral infection during pregnancy in women with and without asthma.
380. New dedicated bifurcated silicone stent placement for stenosis around the primary right carina.
Silicone stenting has been widely used to palliate respiratory symptoms in patients suffering from airway stenosis. Although many types and shapes of stents have been developed, there is no ideal stent for stenosis around the carina between the bronchus to the right upper lobe and the bronchus intermedius (primary right carina). The purpose of this study was to evaluate the feasibility, efficacy, and safety of a new silicone stent designed for treating airway stenosis around the primary right carina.
|